Biomed Central Ltd

SHERPA: Unknown

People

  1. Vickers
    Vickers
  2. Postow
    Postow
  3. D'Angelo
    D'Angelo
  4. Offit
    Offit
  5. Budhu
    Budhu
  6. Motzer
    Motzer
  7. Shoushtari
    Shoushtari
  8. Cheung
    Cheung
  9. Voss
    Voss
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (566)
  2. Solid Tumor Oncology Division (461)
  3. GSK Faculty (295)
  4. Sloan Kettering Institute Postdocs (194)
  5. Hematologic Malignancies, Division of (160)
  6. Population Sciences Research Program (158)
  7. Epidemiology and Biostatistics (153)
  8. Melanoma and Immunotherapeutics Service (148)
  9. Surgery (123)
  10. Survivorship Research (120)
Search Within
Formats
  1. Journal Article (751)
  2. Meeting Abstract (257)
  3. Review (40)
  4. Guidelines (20)
  5. Editorial (11)
  6. Research Letter (7)
  7. Correspondence (4)
  8. Conference Paper (1)
  9. Miscellaneous (1)
Groups
  1. Department of Medicine (566)
  2. Solid Tumor Oncology Division (461)
  3. GSK Faculty (295)
  4. Sloan Kettering Institute Postdocs (194)
  5. Hematologic Malignancies, Division of (160)
  6. Population Sciences Research Program (158)

More Groups

People
  1. Jedd Wolchok (83)
  2. Taha Merghoub (55)
  3. Andrew Vickers (44)
  4. Michael Postow (43)
  5. Matthew Hellmann (30)
  6. Sandra D'Angelo (26)

More People

Years
  1. 2025 (40)
  2. 2024 (60)
  3. 2023 (44)
  4. 2022 (122)
  5. 2021 (91)
  6. 2020 (99)

More Years

Publications
  1. Journal for ImmunoTherapy of Cancer (412)
  2. Breast Cancer Research (67)
  3. BMC Cancer (65)
  4. Genome Biology (47)
  5. Journal of Hematology & Oncology (43)
  6. Journal of Translational Medicine (35)

More Publications

Results (1092)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pharmacologic modulation of tumor glycolysis to improve responses to immune checkpoint blockade therapy
    Meeting Abstract

    Verma, S.; Maniyar, R.; Ko, M.; Budhu, S.; Serganova, I.; Zappasodi, R.; Blasberg, R.; Merghoub, T.; Wolchok, J.; Mangarin, L.
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Single-cell RNA-seq reveals the critical roles of the sting- and MDA5-mediated cytosolic nucleic acid-sensing pathways as well as IFNAR/STAT2 signaling in recombinant MVA-induced antitumor immunity
    Meeting Abstract

    Liu, S.; Mazo, G.; Zhang, T.; Yang, N.; Wang, Y.; Tan, A.; Wang, J.; Choi, J.; Xiang, J. Z.; Merghoub, T.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • A first-in-human phase 1 study of NL-201 in patients with relapsed or refractory cancer
    Meeting Abstract

    Naing, A.; Callahan, M.; Costello, B.; Curti, B.; Hall, E.; Hansen, A.; Long, G.; Joshua, A.; Shankles, B.; Ulge, U.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Updated survival of patients with previously treated metastatic uveal melanoma who received tebentafusp
    Meeting Abstract

    Sacco, J.; Carvajal, R.; Butler, M.; Shoushtari, A.; Hassel, J.; Ikeguchi, A.; Hernandez-Aya, L.; Nathan, P.; Hamid, O.; Piulats, J.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Results from phase IB study of tebentafusp (tebe) in combination with durvalumab (durva) and/or tremelimumab (treme) in metastatic cutaneous melanoma (mCM)
    Meeting Abstract

    Hamid, O.; Hassel, J.; Shoushtari, A.; Meier, F.; Bauer, T.; Salama, A.; Kirkwood, J.; Ascierto, P.; Lorigan, P.; Mauch, C.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Isoform specific anti-TGFβ therapy enhances antitumor efficacy in mouse models of stroma poor cancers
    Meeting Abstract

    Budhu, S.; Gupta, A.; Fitzgerald, K.; Giese, R.; Michel, A.; Holland, A.; Campesato, L. F.; Van Snick, J.; Uyttenhove, C.; Ritter, G.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Phase 3 study of first-line pembrolizumab with and without vibostolimab (anti-TIGIT) in patients with PD-L1-positive metastatic NSCLC
    Meeting Abstract

    Hellmann, M.; Cho, B.; Juergens, R.; Cheng, Y.; de Castro, G.; Erman, M.; Bauman, J.; Takahashi, T.; Schwarzenberger, P.; Zhang, P.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Toxicity of an Fc engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable anti-tumor immunity in patients
    Meeting Abstract

    Knorr, D.; Ravetch, J.; D'Andrea, G.; Vahdat, L.; Klebanoff, C.; Robson, M.
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • First phase 2 results of autologous tumor-infiltrating lymphocyte (TIL; LN-145) monotherapy in patients with advanced, immune checkpoint inhibitor-treated, non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Schoenfeld, A.; Lee, S.; Paz-Ares, L.; Doger, B.; Gettinger, S.; Haefliger, S.; Orcurto, A.; Sukari, A.; Papa, S.; Moreno, J. F. R.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Phase 3 study of pembrolizumab + belzutifan + lenvatinib or pembrolizumab/quavonlimab + lenvatinib versus pembrolizumab + lenvatinib as first-line treatment for advanced renal cell carcinoma
    Meeting Abstract

    Choueiri, T.; Plimack, E.; Powles, T.; Voss, M.; Gurney, H.; Silverman, R.; Perini, R.; Rodriguez-Lopez, K.; Rini, B.
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save